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Abstract We have studied the rela- 
tionship between the apolipoprotein 
E gene (APOE) and the development 
of myoclonus, tremors, rigidity and 
seizures in 168 patients with proba- 
ble early-onset Alzheimer's disease 
(AD). There was a statistically sig- 
nificantly lower risk of tremor for 
carriers of the ~4 allele of APOE. 
This allele was also associated with 
an increased risk of myoclonus. Our 
findings suggest that there may be 
differences in progression and clini- 
cal appearance in early-onset AD re- 
lated to the APOE genotype. 
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Introduction 
Alzheimer's disease (AD) is a clinically heterogeneous 
disorder. It is often accompanied by the development of 
extrapyramidal signs [13], myoclonus [8, 13] and seizures 
[8]. These concomitant clinical features in AD have been 
associated with a more rapid cognitive decline and in- 
creased mortality. Therefore, it has been suggested that 
these features may be markers of disease progression 
[13]. AD has been associated with apolipoprotein E
(apoE) [14]. An increased risk of late-onset and early-on- 
set AD has been observed for carriers of the ~4 allele of 
the apoE gene (APOE*4) compared with patients who 
carry two copies of the wild-type or normal allele e3 
(APOE*3) [3, 14, 15]. The association with the e2 allele 
of the apoE gene (APOE*2) is less clear. Although a num- 
ber of studies have reported a protective ffect of the 
APOE*2 allele on the risk of AD [3, 4], others have re- 
ported an increased AD risk for carriers of this allele [12, 
16]. 
We have shown previously that the APOE gene is as- 
sociated with survival of patients with early-onset AD 
[16]. Here we present a study on the role of the APOE 
gene in the development of concomitant clinical features 
in AD. The aim of this analysis was to examine whether 
the APOE*4 and APOE*2 allele are associated with a dis- 
tinct clinical expression. 
Patients and methods 
Patients were derived from a population-based study of early-onset 
AD. Details concerning the study design have been published else- 
where [15, 16]. The protocol of the study has been reviewed by the 
medical ethics committee of the Erasmus University and Acade- 
mic Hospital Dijkzigt. The series comprised all patients from two 
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areas of the Netherlands, in whom the onset of AD was at age 65 
years or earlier and who were diagnosed as having AD in the pe- 
riod January 1980 to July 1987. The diagnosis of probable arly- 
onset AD was verified according to a standard protocol similar to 
NINCDS-ADRDA criteria. Information was available for 198 
(99%) of the 201 patients who met the inclusion criteria. Informed 
consent was obtained from all patients. For all patients, detailed 
data on family history of dementia in first-, second- and third-de- 
gree relatives were collected [15]. These data were always verified 
by a sibling of the patient. The family history of subjects with no 
first-degree r latives with dementia was classified as negative and 
of those with at least one first-degree relative with dementia s 
positive. APOE typing could be performed in 175 (88%) of the pa- 
tients [15]. 
At entrance into the study, data on medication and on the oc- 
currence of clinical features including myoclonus, tremor, rigidity 
and seizures were collected through medical records from the gen- 
eral hospital where the patient was diagnosed and from the nursing 
home for those patients that were institutionalized. At follow-up in 
1990, medical records from general hospitals and nursing homes 
were up-dated for all patients. The protocol of data collection and 
the relationship of the clinical features to mortality have been de- 
scribed elsewhere [11]. The present analysis is based on the pres- 
ence of clinical features at diagnosis or their occurrence during the 
follow-up of the patients up to 1990. We have considered only 
clinical features that were not related to medication. The mean pe- 
riod of follow-up after diagnosis was 6 years (range 2-11; SD = 2). 
Data on the clinical course were available for 168 (96%) of the 175 
patients in whom APOE was typed. 
All statistical analyses were carried out with the Epidemiologi- 
cal Graphics Estimation and Testing package (EGRET). To adjust 
for censoring of the data which occurred because not every patient 
was followed until death, Cox's proportional hazards model was 
used to estimate the effect of the APOE gene on the occurrence of 
a clinical feature [6]. In addition, we have adjusted all analyses for 
left truncation, which occurred because not all patients were in- 
cluded in our study at the time of diagnosis [10]. 
Results 
General characteristics of the 168 patients are given in 
Table 1 for APOE*3 homozygotes (APOE3E3),  APOE*4  
and APOE*2 carriers. Among APOE*2 carriers, there were 
significantly (P < 0.05) more men (50%) compared with 
APOE*4  (31%) and APOE3E3 (30%) carriers. A family 
history of dementia was found more often among carriers 
of the APOE*4 allele (P < 0.05). APOE genotype was not 
associated with age at onset. Also, the score on the Clini- 
cal Dementia Rating (CDR) scale [9] at diagnosis was not 
associated with the APOE*4 allele [relative risk = 0.7; 95% 
confidence interval (CI) 0.3-1.5; reference APOE3E3[ or 
the APOE*2 allele (relative risk = 1.1; 95% CI 0.3-3.3; 
reference APOE3E3).  
Table 2 shows the risk of concomitant clinical features 
by APOE genotype. APOE*4 carriers had a significant, 
2.2-fold higher risk of myoclonus compared with carriers 
of the APOE3E3 genotype (95% CI: 1 .14.4) ,  A non-sig- 
nificant increase in risk of myoclonus was found for 
APOE*2 carriers. APOE*4 carriers had a significantly 
lower risk of tremors. No significant association was ob- 
served between the APOE genotype and the risk of rigid- 
ity and seizures. The risk of myoclonus and tremors by 
Table 1 Characteristics of the 168 patients with early-onset Alz- 
heimer's disease (AD) 
Clinical feature APOE3E3 APOE*4 APOE*2 
carriers a carriers a 
n = 57 n = 88 n = 24 
Men 17 (30%) 27 (31%) 12 (50%) 
Family history positive 29 (51%) 61 (69%) 12 (50%) 
Mean onset age (SD) 57 (6) 58 (6) 56 (6) 
One subject with the APOE2E4 genotype is included as a 
APOE*4 as well as an APOE*2 carrier 
Table 2 The relative risk (95% confidence interval) of my- 
oclonus, tremor, rigidity and seizures in early-onset AD for 
APOE*4 and APOE*2 carriers compared with the risk for carriers 
of the APOE3E3 genotype 
Clinical feature APOE3E3 APOE*4 a APOE*2 a 
Myoclonus 1 2.2 1.9 
Reference (1.14.4) (0.8-4.9) 
n = 14 b n = 23 n = 9 
Tremor 1 0.4 1.4 
Reference (0.2-0.8) (0.6-3.3) 
n = 14 n = 21 n = 7 
Rigidity 1 0.7 0.8 
Reference (0.4-1.3) (0.4-1.9) 
n = 22 n = 31 n = 9 
Seizures 1 0.8 1. i 
Reference (0.5-1.4) (0.5-2.2) 
n=30 n=42 n= 12 
a One subject with the APOE2E4 genotype is included as a 
APOE*4 as well as an APOE*2 carrier 
b The number of patients who developed the clinical feature over 
time 
APOE genotype is plotted in Fig. 1. Although at each 
point in time after diagnosis the risk of myoclonus was 
higher in APOE*4 and APOE*2 carriers than in APOE3E3 
carriers, in the 11 years of fol low-up 55% (95% CI: 35%- 
78%) of  the APOE3E3 carriers developed myoclonus. Af- 
ter 3 years of fol low-up, the risk of tremors was consis- 
tently lower in APOE*4 than in APOE*2 and APOE3E3 
carriers. 
When stratifying for family history of dementia, the as- 
sociation of the APOE*4 and APOE*2 allele with my- 
oclonus was strongest in those with a negative family his- 
tory of  dementia. The risk of myoclonus was 2.8 (95% CI: 
1.0-7.3) times greater for APOE*4 carriers and 2.3 (95% 
CI: 0.7-7.3) times greater for APOE*2 carriers when 
compared to APOE3E3 carriers (not in table). Among 
those with a positive family history, there was a 1.5-fold 
(95% CI: 0.6-3.8) increased risk associated with the 
APOE*4 allele and a 1.4-fold (95% CI: 0.4-5.8) increase 
with the APOE*2 allele. There was no evidence for effect 
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Discussion 
In this study the occurrence of extrapyramidal signs, my- 
oclonus and seizures was assessed through medical 
records. The diagnosis of the clinical features was there- 
fore not standardized and their occurrence may not always 
have been recorded. To overcome this problem, we lim- 
ited our study to those features that required special med- 
ical and nursing care and consequently are well diagnosed 
and most likely reported in the medical records. In addi- 
tion, we relied on neurological examinations by trained 
neurologists as well as by nursing home physicians. Al- 
though in the Netherlands the latter perform neurological 
examinations routinely at admission of an AD patient o 
the nursing home, the reliability of their diagnosis may 
vary considerably. However, we have previously shown 
the occurrence of extrapyramidal signs, tremors and rigid- 
ity, to be strongly associated (P = 0.001) while neither 
tremors nor rigidity were associated with the occurrence 
of myoclonus or seizures [11]. This suggests that tremor, 
one of the features associated with APOE, was suitable 
distinguished by the participating physicians from the 
other associated feature, myoclonus. Also, it is important 
to note that in order to bias our results the misclassifica- 
tion in the clinical features must have occurred differen- 
tially in APOE3E3, APOE*4 and APOE*2 carriers in or- 
der to introduce an artificial relationship. It is unlikely 
that this has happened systematically, asthe nursing home 
staff were not aware of the patient's APOE genotype. 
Most likely, bias due to misdiagnosis has occurred ran- 
domly and independent of the APOE genotype in our 
study. The effect of such misclassification is most likely 
that existing relationships are diminished rather than non- 
existing associations being created. 
Our findings suggest hat there may be differences in 
the clinical course of early-onset AD related to the APOE 
genotype. One earlier study failed to show an association 
[1]. However, that study was based on late-onset AD and 
the number of patients was small 07 = 60) while the fol- 
low-up period was limited (3 years) [1]. Our study shows 
that APOE*4 carriers have a significantly decreased risk 
of developing tremors. Although there is considerable 
controversy concerning the role of APOE in the survival 
of AD patients [2, 5], our study and those of others sug- 
gest that the APOE*4 allele is associated with a slower 
progression of AD and a reduced risk of mortality [1, 7, 
16]. Our earlier finding of a lower mortality for early-on- 
set AD patients who carry the APOE*4 allele [16] agrees 
with the lower risk of tremors, because the latter probably 
indicate an advanced stage of AD [13]. There are two pos- 
sible explanations for these findings. Firstly, the diagnosis 
of AD occurs earlier in APOE*4 carriers than in other pa- 
tients, leading to an artificially prolonged survival. Sec- 
ondly, the APOE*4 allele is truly associated with a slow 
progression of AD. The first explanation is plausible, e.g. 
because APOE*4 carriers are more likely to have a posi- 
tive family history [15] or a history of cardiovascular dis- 
ease and may be more alert when initial symptoms appear. 
However, in our population the age of onset and the sever- 
ity of the dementia t diagnosis as measured by the CDR 
score was similar in patients with and without the 
APOE*4 allele [15]. Adjusting the analysis for the CDR 
score at diagnosis or the duration of dementia t diagnosis 
did not change any of our conclusions, suggesting that the 
explanation of a relatively early diagnosis in APOE*4 
carriers is unlikely. In addition, our finding that the risk of 
myoclonus was significantly increased for APOE*4 carri- 
ers challenges this hypothesis, since the occurrence of 
both tremors and myoclonus has been shown to indicate 
advanced stages of AD [13]. 
The increased risk of myoclonus for APOE*4 carriers 
cannot be explained by disease progression but suggests 
an unusual early expression of myoclonus in early-onset 
AD patients with the APOE*4 allele. The hypothesis of a 
distinct clinical appearance of patients is further sup- 
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ported by the finding that the association was strongest in 
those with a negative family history. It is important o 
note that the occurrence of myoclonus was not limited to 
APOE*4 carriers. APOE3E3 carriers may also develop 
myoclonus, albeit at a later stage. The finding that carriers 
of the APOE*2 allele have a risk of tremors imilar to that 
of carriers of the APOE3E3 genotype, while at the same 
time the risk of myoclonus for APOE*2 carriers is similar 
to that for APOE*4 carriers, seems contradictory. How- 
ever, our findings on the APOE*2 allele are based on a 
small number of patients. 
This is the first study to suggest hat there may be dif- 
ferences in progression and clinical appearance in early- 
onset AD related to the APOE genotype. An important 
advantage of our study is the population-based design in 
which patients have been followed for an extended period. 
However, our findings are based on a specific subgroup of 
AD patients with an early onset of AD. Further, we have 
not collected ata on the occurrence of the features under 
study by a standardized clinical examination. Our find- 
ings therefore remain to be confirmed by other studies on 
the clinical course of AD. 
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